Antrodia cinnamomea Extract Modulating Th17 Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases and inflammatory conditions related to Th17 cells lack effective modulation strategies, and the potential therapeutic effects of Antrodia cinnamomea on these cells are not well understood.

Innovation Solution

A pharmaceutical composition comprising Antrodia cinnamomea extract is used to modulate Th17 cells, inhibiting their differentiation, which is achieved through the extraction of the fungus's fruiting body or mycelium using solvents like ethanol or ethyl acetate, and administered to subjects to treat diseases such as systemic lupus erythematosus and psoriasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for autoimmune diseases, then existing therapeutic options are available, but they lack effective modulation strategies for Th17 cells

Engineering Contradiction:

Improveeffectiveness of Th17 cell modulationVSAvoidmodulation strategy availability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts the active components from Antrodia cinnamomea through solvent extraction processes (ethanol, ethyl acetate, or water extraction) to obtain the therapeutic agent that specifically modulates Th17 cells, addressing the lack of effective modulation strategies

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If Antrodia cinnamomea extract is used to inhibit Th17 cell differentiation, then therapeutic effect is improved, but the extraction process requires specific solvents and conditions

Engineering Contradiction:

Improvetherapeutic effectVSAvoidextraction process complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent provides multiple extraction parameter options (different solvents: ethanol, ethyl acetate, or water; different ratios; different extraction times) to optimize the extraction process while maintaining therapeutic effectiveness, making the manufacture more flexible and adaptable

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If Th17 cell differentiation is inhibited, then autoimmune disease symptoms are reduced, but the treatment requires specific administration to subjects in need

Engineering Contradiction:

Improveautoimmune disease symptomsVSAvoidtreatment administration

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent uses Antrodia cinnamomea extract as an intermediary substance that mediates the treatment between the subject and the Th17 cells, providing a safe and effective way to inhibit Th17 cell differentiation and treat autoimmune diseases

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS9603882B2Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells

Publication Date: 2017.03.28 IND TECH RES INST

AI summary

The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.